Schwab Charles Investment Management Inc. lifted its stake in shares of Synergy Pharmaceuticals Inc (NASDAQ:SGYP) by 11.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,051,408 shares of the biopharmaceutical company’s stock after purchasing an additional 106,222 shares during the quarter. Schwab Charles Investment Management Inc. owned about 0.43% of Synergy Pharmaceuticals worth $2,345,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. raised its stake in shares of Synergy Pharmaceuticals by 71.3% during the third quarter. JPMorgan Chase & Co. now owns 3,405,377 shares of the biopharmaceutical company’s stock worth $8,820,000 after purchasing an additional 1,417,177 shares during the last quarter. Alyeska Investment Group L.P. grew its holdings in Synergy Pharmaceuticals by 42.0% during the third quarter. Alyeska Investment Group L.P. now owns 2,355,681 shares of the biopharmaceutical company’s stock worth $6,831,000 after acquiring an additional 696,911 shares during the period. OxFORD Asset Management LLP grew its holdings in Synergy Pharmaceuticals by 42.5% during the third quarter. OxFORD Asset Management LLP now owns 2,040,297 shares of the biopharmaceutical company’s stock worth $5,784,000 after acquiring an additional 608,402 shares during the period. Hikari Power Ltd grew its holdings in Synergy Pharmaceuticals by 26.7% during the fourth quarter. Hikari Power Ltd now owns 1,900,000 shares of the biopharmaceutical company’s stock worth $4,237,000 after acquiring an additional 400,000 shares during the period. Finally, Wells Fargo & Company MN grew its holdings in Synergy Pharmaceuticals by 18.2% during the third quarter. Wells Fargo & Company MN now owns 219,676 shares of the biopharmaceutical company’s stock worth $638,000 after acquiring an additional 33,802 shares during the period. Institutional investors and hedge funds own 53.08% of the company’s stock.

How to Become a New Pot Stock Millionaire

Shares of Synergy Pharmaceuticals Inc (NASDAQ SGYP) opened at $1.91 on Friday. The company has a debt-to-equity ratio of -21.05, a current ratio of 4.33 and a quick ratio of 3.88. The firm has a market capitalization of $476.05, a price-to-earnings ratio of -1.89 and a beta of 1.26. Synergy Pharmaceuticals Inc has a twelve month low of $1.68 and a twelve month high of $4.86.

Synergy Pharmaceuticals (NASDAQ:SGYP) last posted its earnings results on Thursday, March 1st. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.19) by $0.03. The company had revenue of $9.40 million for the quarter, compared to analyst estimates of $7.12 million. Synergy Pharmaceuticals had a negative return on equity of 652.66% and a negative net margin of 1,333.76%. The business’s revenue for the quarter was up 840.0% compared to the same quarter last year. equities research analysts forecast that Synergy Pharmaceuticals Inc will post -0.52 EPS for the current fiscal year.

A number of brokerages recently weighed in on SGYP. BidaskClub raised Synergy Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, January 23rd. Cantor Fitzgerald reaffirmed a “buy” rating and set a $10.00 price objective on shares of Synergy Pharmaceuticals in a report on Thursday, January 25th. Oppenheimer reaffirmed a “market perform” rating and set a $10.00 price objective on shares of Synergy Pharmaceuticals in a report on Friday, January 5th. CIBC reaffirmed a “market perform” rating on shares of Synergy Pharmaceuticals in a report on Friday, January 5th. Finally, Citigroup lowered Synergy Pharmaceuticals to a “market perform” rating in a report on Friday, January 5th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $8.08.

COPYRIGHT VIOLATION NOTICE: “Schwab Charles Investment Management Inc. Has $2.35 Million Stake in Synergy Pharmaceuticals Inc (SGYP)” was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The legal version of this story can be read at https://www.watchlistnews.com/schwab-charles-investment-management-inc-has-2-35-million-stake-in-synergy-pharmaceuticals-inc-sgyp/1959729.html.

Synergy Pharmaceuticals Company Profile

Synergy Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s product candidates include TRULANCE (plecanatide) and dolcanatide. The Company is engaged in the discovery, research and development efforts around analogs of uroguanylin for the treatment of GI diseases and disorders.

Want to see what other hedge funds are holding SGYP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Synergy Pharmaceuticals Inc (NASDAQ:SGYP).

Institutional Ownership by Quarter for Synergy Pharmaceuticals (NASDAQ:SGYP)

Receive News & Ratings for Synergy Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synergy Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.